Inovio Pharmaceuticals’ vaccine for coronavirus could be ready by year’s end

Since news of the coronavirus outbreak emerged, in contrast to the sell-off in the broader market, companies associated with the COVID-19 space have seen valuations significantly increase.This week, the baton was handed over to Inovio Pharmaceuticals (INO). Shares of the infectious disease warrior have shot up nearly 130% this week, following the announcement of development timelines for its COVID-19 vaccine (INO-4800) using its DNA vaccine platform.Inovio’s COVID-19 vaccine, INO-4800, was developed in just 3 hours once the COVID-19 sequence was deposited in data banks for public access. This, according to Maxim’s Jason McCarthy, is testament to the company’s ability to …read more

Source:: Yahoo Finance

Discover Tomorrow’s Winning Stocks!
Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.